Sonalleve® MR-HIFU
Uterine Fibroids
Key Facts
About Profound Medical
Profound Medical is pioneering a new category of incision-free, image-guided therapeutic ablation. The company's core technology platform integrates real-time magnetic resonance imaging (MRI) with therapeutic ultrasound to enable precise, predictable, and radiation-free tissue ablation. With its TULSA-PRO® system commercially available in the U.S., Europe, and other markets, Profound is targeting the large and growing market for prostate disease treatment, including prostate cancer and benign prostatic hyperplasia (BPH). The company is publicly traded and continues to advance clinical evidence and expand commercial adoption.
View full company profileAbout Profound Medical
Profound Medical is pioneering a new category of incision-free, image-guided therapeutic ablation. The company's core technology platform integrates real-time magnetic resonance imaging (MRI) with therapeutic ultrasound to enable precise, predictable, and radiation-free tissue ablation. With its TULSA-PRO® system commercially available in the U.S., Europe, and other markets, Profound is targeting the large and growing market for prostate disease treatment, including prostate cancer and benign prostatic hyperplasia (BPH). The company is publicly traded and continues to advance clinical evidence and expand commercial adoption.
View full company profileOther Uterine Fibroids Drugs
| Drug | Company | Phase |
|---|---|---|
| Esmya® (ulipristal acetate) | Organon | Approved |